Patents by Inventor Uma Sinha

Uma Sinha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Formulations of triphenyl calcilytic compounds
    Patent number: 12357576
    Abstract: The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: July 15, 2025
    Assignee: CALCILYTIX THERAPEUTICS, INC.
    Inventors: Uma Sinha, Ananth Sridhar, Leena Prasad, Ali Komeyli
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20250186563
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: October 8, 2024
    Publication date: June 12, 2025
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • METHODS OF TREATING TTR AMYLOIDOSIS USING AG10
    Publication number: 20250041276
    Abstract: Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
    Type: Application
    Filed: July 16, 2024
    Publication date: February 6, 2025
    Inventors: Uma SINHA, Satish RAO
  • 1H-1,2,3-TRIAZOLE-4-CARBOXYLIC ACIDS FOR TREATMENT OF HYPEROXALURIA AND KIDNEY STONES
    Publication number: 20240423961
    Abstract: Described herein are methods for treating hyperoxaluria in a subject with Compound 1, represented by the formula: (Compound 1), a tautomer, a pharmaceutically acceptable salt, a hydrate, a solvate, or a combination thereof. In particular, Compound 1 is Compound 1a or a tautomer thereof in a monosodium and monohydrate form. Also described are methods for treating or preventing kidney stones. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
    Type: Application
    Filed: October 11, 2022
    Publication date: December 26, 2024
    Inventors: Jonathan C. FOX, Uma SINHA, Satish RAO
  • Methods of treating TTR amyloidosis using AG10
    Patent number: 12070449
    Abstract: Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: August 27, 2024
    Assignee: EIDOS THERAPEUTICS, INC.
    Inventors: Uma Sinha, Satish Rao
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20240189401
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 14, 2023
    Publication date: June 13, 2024
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20240082367
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidoes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: November 2, 2023
    Publication date: March 14, 2024
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDS
    Publication number: 20240074978
    Abstract: The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.
    Type: Application
    Filed: June 29, 2023
    Publication date: March 7, 2024
    Inventors: Uma SINHA, Ananth SRIDHAR, Leena PRASAD, Ali KOMEYLI
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 11839646
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: December 12, 2023
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR
    Publication number: 20230383276
    Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.
    Type: Application
    Filed: March 22, 2023
    Publication date: November 30, 2023
    Inventors: Genmin Lu, Pamela B. Conley, Uma Sinha
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20230000957
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: January 5, 2022
    Publication date: January 5, 2023
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • PROCESS FOR MAKING RECOMBINANT ANTIDOTE TO FACTOR XA INHIBITOR
    Publication number: 20220098565
    Abstract: Disclosed are methods and isolated cells useful for the improved production of function fXa derivative protein that acts as a fXa inhibitor antidote. One aspect relates to an isolated cell comprising the r-Antidote polynucleotide and Furin polynucleotide. Another aspect relates to a method for preparing the cleaved two-chain r-Antidote by expressing, in a cell, the pre-processed r-Antidote polypeptide and a Furin polypeptide.
    Type: Application
    Filed: July 28, 2021
    Publication date: March 31, 2022
    Inventors: Genmin Lu, Pamela B. Conley, Uma Sinha
  • FORMULATIONS OF TRIPHENYL CALCILYTIC COMPOUNDS
    Publication number: 20220040112
    Abstract: The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.
    Type: Application
    Filed: August 3, 2021
    Publication date: February 10, 2022
    Inventors: Uma SINHA, Ananth SRIDHAR, Leena PRASAD, Ali KOMEYLI
  • METHODS OF TREATING TTR AMYLOIDOSIS USING AG10
    Publication number: 20220016081
    Abstract: Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject.
    Type: Application
    Filed: May 27, 2021
    Publication date: January 20, 2022
    Inventors: Uma SINHA, Satish RAO
  • INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
    Publication number: 20210379163
    Abstract: The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
    Type: Application
    Filed: February 16, 2021
    Publication date: December 9, 2021
    Inventors: Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley
  • ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20210340515
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: March 9, 2021
    Publication date: November 4, 2021
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Methods of treating TTR amyloidosis using AG10
    Patent number: 11058668
    Abstract: Described herein are methods for treating transthyretin (TTR) amyloidosis in a subject. The methods include specific dosing regimens that have great efficacy in treating the subjects and that are well tolerated in subjects.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: July 13, 2021
    Assignee: EIDOS THERAPEUTICS, INC.
    Inventors: Uma Sinha, Satish Rao
  • UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20210085762
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Application
    Filed: July 30, 2020
    Publication date: March 25, 2021
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach
  • Antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10954503
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: March 23, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
    Patent number: 10765726
    Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 8, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Athiwat Hutchaleelaha, Stanley J. Hollenbach